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Background: Amplification of MYCN oncogene is an established marker indicating aggressive tumor progression of
neuroblastoma (NBL). But copy number analyses of MYCN gene in ganglioneuroblastoma (GNBL) and
ganglioneuroma(GN) is poorly described in the literature. In the study, we evaluated the copy number aberrations
of MYCN gene in clinical samples of NBLs, GNBLs and GNs and analyzed their association with clinical outcome of
the patients.
Methods: In this study, we analyzed MYCN gene and chromosome 2 aneusomy by using fluorescence in situ
hybridization (FISH) method in a total of 220 patients with NBL, GNBL and GN cases. Kaplan-Meier curves were
generated by using SPSS 12.0 software.
Results: Of 220 patients, 178 (81.0%) were NBLs, 32 (14.5%) were GNBLs and 10 (4.5%) were GNs. MYCN gain is a
recurrent genetic aberration of neuroblastic tumors (71.8%, 158/220), which was found in 129 NBLs (58.6%,
129/220), 25 GNBLs (11.4%, 25/220) and 4 GN cases (1.8%, 4/220). However, MYCN amplification was only present in
24 NBL tumors (13.5%, 24/178) and 1 GNBL case (3.1%, 1/32). Kaplan-Meier survival analysis indicated that MYCN
amplification is significantly correlated with decreased overall survival in NBLs (P=0.017). Furthermore, a better
prognosis trend was observed in patients with MYCN gain tumors compared with those with MYCN gene normal
copy number tumors and MYCN amplification tumors (P=0.012).
Conclusions: In summary, the frequency of MYCN amplification in NBLs is high and is rarely observed in GNBLs and
GNs, which suggest MYCN plays an important role in neuroblastic tumors differentiation. MYCN gain appeared to
define a subgroup of NBLs with much better outcome and classification of MYCN gene copy number alteration as
three groups (amplification, gain and normal) can provide a powerful prognostic indicator in NBLs.
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Table 1 Patient characteristics
Characteristics GN GNBL NBL
Patients [no. % ] 10 32 178
Median age (years) 3 3.5 1.8
Male/female ratio 4/6 14/18 113/65
Sites
adrenals 1 12 67
thorax 6 12 31
abdomen 2 8 50
pelvis 0 0 10
others 1 0 20
MYCN status
normal 6 6 25
gain 4 25 129
amplification 0 1 24
GN :Ganglioneuroma; GNBL: Ganglioneuroblastoma; NBL: Neuroblastoma.
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Peripheral neuroblastic tumors (NTs) including neuro-
blastoma(NBL), ganglioneuroblastoma(GNBL), and gang-
lioneuroma(GN) comprise one of the most common
groups of neoplastic disease in infants and children. NBL
and GNBL are considered malignant. In contrast, GNs are
considered as benign tumors. In histology, NBL, GNBL,
and GN can be conceptualized as three maturational man-
ifestations of a common neoplasm [1].
Amplification of MYCN oncogene is an established mar-
ker indicating aggressive tumor progression of NBL [2,3].
Brodeur et al. [4] were the first to show thatMYCN ampli-
fication occurs in a substantial subset of primary untreated
NBLs and is highly correlated with advanced stage. Seeger
et al. [5,6] then demonstrated a strong association with
rapid disease progression and a poor prognosis. Analysis of
MYCN remains an essential component of disease evalu-
ation for newly diagnosed NBL patients and serves as a
paradigm for the utility of molecular biologic information
in cancer treatment stratification [7-9]. MYCN is vital for
proliferation, migration and stem cell homeostasis while
decreased levels are associated with terminal neuronal dif-
ferentiation [10]. On the other hand, downregulation of
MYCN leads to decreased proliferation and differentiation,
emphasizing the importance of MYC signaling in NBL
biology [11,12]. But copy number status of MYCN gene in
GNBL and GN is poorly described in the literature [13].
In the study, we evaluated the copy number aberrations
of MYCN gene in formalin-fixed, paraffin-embedded clin-
ical samples of NBLs, GNBLs and GNs and analyzed their
association with clinical outcome of the patients.
Methods
Tumor tissue and patient information
Formalin-fixed, paraffin-embedded clinical samples taken
from 220 pediatric neuroblastic tumors enrolled on thera-
peutic or nontherapeutic protocols between 2009 and
2011. Specimen was limited to patients whose diagnosis of
neuroblastic tumors was based on histologic and immu-
nohistochemistry examination. Selected clinical and la-
boratory data (e.g., age at diagnosis, sex, tumor site) were
retrieved from the Beijing Children Hospital. The patient
characteristics are described in Table 1.
Fluorescence in situ hybridization (FISH)
MYCN gene was investigated by interphase FISH on par-
affin sections as previously described [14]. Briefly, the
4 μm-thick tissue sections were deparaffinized and
pressure-cooked in 1mM ethylene diamine tetraacetic
acid (EDTA) buffer for 3 min. The tissues were then
digested in 0.1% pepsin solution at 37°C for 20 min,
dehydrated and added with the appropriate probes.
MYCN SG/CEP2 SO probe is used in this study (Vysis,
Abbott Laboratories, Abbott Park, IL). The slides wereincubated at 80°C for 25 min and at 45°C for 2 days.
The slides were then washed in post-hybridization
buffers, stained with anti-fade solution containing 4’ ,6-
diamidino-2-phenylindole (DAPI; Vector Labs, Burlingame,
CA) and examined using a fluorescence microscope (BX51;
Olympus, Tokyo, Japan) by two investigators independ-
ently. Slides with known structural or numerical abnormal-
ity for the above probes were used as positive controls, and
a case of reactive hyperplasia of the tonsil was used as a
negative control.
FISH scoring scheme
Fluorescence microscopy was performed with a BX51
microscope equipped with filter set for FITC, Texas red,
and DAPI. Each sample was analyzed to determine the
origin of the amplification unit (extrachromosomal
double minutes or intrachromosomal homogeneously
staining regions) and the proportion of cells with ampli-
fied MYCN genes. The FISH signals were scored in 200
no overlapping nuclei per core, independently by two
investigators (M Wang and LP Gong.), and the consen-
sus was recorded. Four cellular groups were defined as
previous study [15]. No Alteration: cells with 2 MYCN
signals and 2 CEP2 signals; Amplification: The number
of MYCN signals is at least 10 copies greater than the
control probe signals;Loss/Imbalance:Presence of at least
2 MYCN signals and increased CEP2 signals;Gain: The
number of MYCN signals is 1–9 copies more than CEP2
signals.
Statistical analysis
SPSS 12.0 software (SPSS, Chicago, IL) was used to analyze
differences in neuroblastic tumor characteristics among
the patient groups. The χ2 test or two-tailed Fisher’s exact
test was used to compare the predictive values of each
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ered statistically significant. Kaplan-Meier curves were
generated by using SPSS 12.0 software.
Results
Clinical features
We analyzed a panel of 220 pediatric patient samples
comprising 178 NBLs, 32 GNBLs, and 10 GNs. Patient
characteristics are summarized in Table 1. There was a
male predominance in NBL disease group, with the male
to female ratio being 1.7:1. The median age at diagnosis
was 3 years for GNs, 3.5 years for GNBLs and 1.8 years
for NBLs. Patients with NBL were significantly younger
than patients with GN and GNBL (P < 0.001). The dis-
tribution of these three diseases generally follows the
distribution of the sympathetic ganglia. In our study,
about 36.4% (80/220) tumors arise in adrenal gland. In
addition, adrenal involvement at diagnosis was 1 case for
GN, 12 cases for GNBL and 67 cases for NBL.Morphology features
Neuroblastic tumors were divided into three histological
subtypes on morphologic criteria of neuroblastic tumors
which was recommendations by the International Neuro-
blastoma Pathology Committee [16]. GN, a fully differen-
tiated tumor, is characterized by a mixture of mature
schwann cells and ganglion cells (Figure 1A). GNBL has
primitive neuroblasts along with maturing ganglion cells
(Figure 1B); the number and arrangement of the cells vary
so the tumor assumes a wide range of appearances. NBL,
the least differentiated, resembles the fetal adrenal medulla
and is composed of primitive neuroblasts (Figure 1C).Figure 1 Representative HE image of neuroblastic tumors. A, Ganglion
Ganglioneuroblastoma: Increased schwannian stroma. C, Neuroblastoma: A
cytoplasm.GNBLs and GNs are usually of favorable histology. In fact,
GN is considered a benign neuroblastic tumor.
MYCN gene status analysis
MYCN gene FISH analysis was successful in all cases of
GN, GNBL and NBL, and the results are detailed in
Table 1.MYCN status was determined in light of chromo-
some 2 copy number. No cases showed loss of centromere
2 and MYCN. But in total, 158 cases with MYCN gene
gain also showed gain of centromere 2, suggesting poly-
ploidy in these cases.
Among 178 NBL cases, 153 (85.9%) were MYCN gene
alterations, including 24 cases (13.5%) with MYCN amp-
lification [Figure 2A] and 129 cases (72.5%) with MYCN
gain [Figure 2B]. MYCN gene normal [Figure 2C] was
only found in 25 cases (14.0%) of NBL, which was sig-
nificantly lower than in GNBL and in GN (p<0.05).
In GN and GNBL cases, six of ten (40.0%) and six of
thirty-two (18.8%) cases showed no aberration of MYCN
gene, respectively. The frequency of MYCN gain was sig-
nificantly higher in GNBL (78.1%, 25/32) than in GN
(40.0%, 4/10) (p<0.05).
Prognostic analysis
Sixty-seven NBL cases had follow-up information avail-
able, with 50 survived and 17 died at the time of writing
up of the study. The patients typically received multiagent
chemotherapy. The survival time ranged from 0 to 47
months and the average survival time was 37.4 months. A
significant trend was observed between MYCN gene amp-
lification tumors and poor outcome compared with those
with no amplification of MYCN gene patients (p=0.017)
(Figure 3A). Interestingly,the Kaplan-Meier survivaleuroma: Mature ganglion cell with schwannian stroma. B,
monotonous population of hyperchromatic cells with scant
Figure 2 Representative FISH image of neuroblastic tumor cells displaying MYCN gene status. A: Amplification:The number of MYCN
signals (green) is more than 10 copies of the CEP2 probe signals (red). B: Gain:The number of MYCN signals (green) is 1 copy greater than the
CEP2 probe signals; C: No Alteration: Cells with MYCN signals (green) showing the same numbers of the CEP2 probe signals. (DAPI counterstain,
original magnification ×1000).
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patients with MYCN gene gain tumors compared with
those with MYCN gene normal tumors (p=0.012)
(Figure 3B).
Discussion
The peripheral neuroblastic tumour group includes
NBL, GNBL and GN. NBL is the most common extra-
cranial solid tumour of childhood and the incidence of
pediatric neuroblastoma are increasing [17,18]. MYCN
gene amplification is a known molecular marker for ag-
gressive progression of NBL [4]. In the study, we evalu-
ated the histological presentation and MYCN gene copy
number in 220 pediatric neuroblastic tumors, which in-
clude 178 NBLs, 32 GNBLs and 10 GNs and analyzedFigure 3 Overall survival analysis. A. MYCN amplification is correlated w
correlated with decreased overall survival and MYCN gene gain is correlatetheir association with clinical outcome of the patients.
To our knowledge, this is the first article for MYCN
gene and chromosome 2 aneusomy analyses by using
fluorescence in situ hybridization (FISH) method in
chinese pediatric patients.
Our study reaffirmed the need for MYCN copy num-
ber to be determined in light of chromosome 2 copy
number. MYCN copy number had been determined by
southern blot analysis [19]. After 1993, fluorescence in
situ hybridization (FISH) was used to determine the
presence of MYCN amplification [20,21]. In these stud-
ies, the results of southern blotting and FISH analysis
were prospectively compared and a MYCN copy number
of ≥ 10 was determined to be the optimal cutoff by FISH
[20], as the vast majority of amplified tumors have veryith decreased overall survival in NBL. P=0.017. B. MYCN amplification is
d with good outcome in NBL. P=0.012.
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southern blotting, any normal cells in the tissue were
included in the measurement, whereas by FISH, each
tumor nucleus was visualized directly and simultaneous
cohybridization with a specific chromosome probe is of
great value in predicting the prognosis of patients [22].
FISH has a higher sensitivity because it detects the
MYCN copy number on the single-cell level and allows
correlation of morphologic details. In our estimation,
FISH is a practical, useful and reliable method for ana-
lysis of MYCN copy number in neuroblastic tumors.
Our results showed that aberrant MYCN copy number
was detected in 153 (85.9%) of 178 NBLs, with amplifi-
cation constituting 24 (13.5%), gain 129(72.4%). In con-
trast, MYCN amplification is only observed in one
GNBL case (1/32, 3.1%) and no GN cases (0/10, 0%).
Moll A et al. [23] also reported that no amplification of
the MYCN-oncogene was found in mixed hepatoblas-
toma and teratoma of the liver in a 3-year-old boy. Wan,
T.S et al. [24] investigated 12 NBL patients for MYCN
amplification by FISH and found that 16.7% cases had
MYCN amplification. Angelini,P et al. [13] reported that
only about 2% had MYCN gene amplified tumours in
232 GNBL patients. Our results also showed that the
frequency of MYCN gene gain was significantly higher
in GNBL (78.1%, 25/32) and NBL (72.5%, 129/178) than
in GN (40.0%, 4/10). Toraman,A.D et al. [25] found that
chromosomal gains displayed by chromosomes and
chromosome loci were 2p25 approximately pter (60%) in
five GNBL cases by comparative genomic hybridization.
Truong LN et al. [26] also detected MYCN oncogenes in
malignant brain tumors by using multiplex ligation
dependent probe amplification (MLPA). Thus, higher
frequency of MYCN gene aberrations in undifferentiated
or less differentiated tumors indicates an important
function of MYCN gene in tumor malignancy.
MYCN amplification is an established marker indicat-
ing aggressive tumor progression of NBL [27]. Our data
also showed that MYCN amplification is correlated with
decreased overall survival in NBL (P=0.017) (Figure 3A).
More significantly, we demonstrated for the first time
that the presence of extra copies of MYCN gene is an in-
dependent prognostic factor for NBL in our case series.
The patients with MYCN gene gain had a significantly
longer mean survival time than those with normal
MYCN gene copy number (P=0.012) (Figure 3B). In our
data, NBL cases with MYCN gene gain also showed gain
of centromere 2, suggesting polyploidy in these cases. In
1991, look et al. [28] found that NBL patietns treated
with cyclophosphamide-doxorubicin, hyperdiploidy was
closely associated with long-term disease-free survival
(greater than 90% of cases), while diploidy invariably
predicted early treatment failure (P <0.001). Recently,
George et al. had also found that NB patients withhyperdiploidy plus no amplified MYCN confers a favor-
able prognosis [29], which is in line with our study. Fur-
thermore, they also found that hyperdiploidy plus no
amplified MYCN NBL patients may respond well to con-
temporary chemotherapy, and could be spared intensive
myeloablative therapy with stem-cell rescue [29]. Thus,
the classification of MYCN gene status as three groups
by FISH may provide more powerful prognostic indica-
tor and better treatment options in NBL.
Conclusions
In summary, using simple and easily applicable FISH
technique we showed in the present study that the fre-
quency of MYCN amplification in NBLs is high and is
rarely observed in GNBLs and GNs, which suggest
MYCN gene play an important role in neuroblastic
tumors differentiation. Furthermore, the copy number
gain of MYCN gene locus appeared to define a subgroup
of NBL with much better outcome and classification of
MYCN gene copy number alteration as three groups
(amplification, gain and normal) can provide a powerful
prognostic indicator in NBL.
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